國立虎尾科技大學 |

Antiviral Drug Discovery and Development

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Antiviral Drug Discovery and Development/ edited by Xinyong Liu, Peng Zhan, Luis Menéndez-Arias, Vasanthanathan Poongavanam.
其他作者:	Liu, Xinyong.
面頁冊數:	XI, 357 p. 142 illus., 64 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmacology. -
電子資源:	https://doi.org/10.1007/978-981-16-0267-2
ISBN:	9789811602672

Antiviral Drug Discovery and Development
Antiviral Drug Discovery and Development[electronic resource] /edited by Xinyong Liu, Peng Zhan, Luis Menéndez-Arias, Vasanthanathan Poongavanam. - 1st ed. 2021. - XI, 357 p. 142 illus., 64 illus. in color.online resource. - Advances in Experimental Medicine and Biology,13222214-8019 ;. - Advances in Experimental Medicine and Biology,889.

1 Antiviral Drugs Against Herpesviruses -- 2 An Update on Antiretroviral Therapy -- 3 Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and their Inhibition -- 4 LEDGINs, Inhibitors of the Interaction between HIV-1 Integrase and LEDGF/p75, are Potent Antivirals with a Potential to Cure HIV Infection -- 5 Moving Fast Towards Hepatitis B Virus Elimination -- 6 Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection -- 7 Phytoconstituents as Lead Compounds for Anti-dengue Drug Discovery -- 8 Anti-influenza Drug Discovery and Development: Targeting the Virus and its Host by all -- 9 Search, Identification and Design of Effective Antiviral Drugs against Pandemic Human Coronaviruses -- 10 Peptide Based Antiviral Drugs -- 11 Covalent Antiviral Agents -- 12 Safe-in-Man Broad Spectrum Antiviral Agents -- 13 Exploiting Ubiquitin ligases for Induced Target Degradation as an Antiviral Strategy. .

This book summarizes state-of-the-art antiviral drug design and discovery approaches starting from natural products to de novo design, and provides a timely update on recently approved antiviral drugs and compounds in advanced clinical development. Special attention is paid to viral infections with a high impact on the world population or highly relevant from the public health perspective (HIV, hepatitis C, influenza virus, etc.). In these chapters, limitations associated with adverse effects and emergence of drug resistance are discussed in detail. In addition to classical antiviral strategies, chapters will be dedicated to discuss the non-classical drug development strategies to block viral infection, for instance, allosteric inhibitors, covalent antiviral agents, or antiviral compounds targeting protein–protein interactions. Finally, current prospects for producing broad-spectrum antiviral inhibitors will be also addressed. The book is distinctive in providing the most recent update in the rapidly evolving field of antiviral therapeutics. Authoritative reviews are written by international scientists well known for their contributions in their topics of research, which makes this book suitable for researchers not only within the antiviral research community but also attractive to a broad audience in the drug discovery field. This book covers molecular structures and biochemical mechanisms mediating the antiviral effects, while discussing various ligand design strategies, which include traditional medicinal chemistry, computational chemistry, and chemical biology approaches. The book provides a comprehensive review of antiviral drug discovery and development approaches, particularly focusing on current innovations and future trends.

ISBN: 9789811602672

Standard No.: 10.1007/978-981-16-0267-2doiSubjects--Topical Terms:

583819
Pharmacology.

LC Class. No.: RM1-950

Dewey Class. No.: 615

Antiviral Drug Discovery and Development
LDR:04197nam a22004095i 4500 001 1046211
003 DE-He213
005 20210930155454.0
007 cr nn 008mamaa
008 220103s2021 si | s |||| 0|eng d
020 $a 9789811602672 $9 978-981-16-0267-2
024 7 $a 10.1007/978-981-16-0267-2 $2 doi
035 $a 978-981-16-0267-2
050 4 $a RM1-950
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615 $2 23
245 1 0 $a Antiviral Drug Discovery and Development $h [electronic resource] / $c edited by Xinyong Liu, Peng Zhan, Luis Menéndez-Arias, Vasanthanathan Poongavanam.
250 $a 1st ed. 2021.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2021.
300 $a XI, 357 p. 142 illus., 64 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 2214-8019 ; $v 1322
505 0 $a 1 Antiviral Drugs Against Herpesviruses -- 2 An Update on Antiretroviral Therapy -- 3 Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and their Inhibition -- 4 LEDGINs, Inhibitors of the Interaction between HIV-1 Integrase and LEDGF/p75, are Potent Antivirals with a Potential to Cure HIV Infection -- 5 Moving Fast Towards Hepatitis B Virus Elimination -- 6 Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection -- 7 Phytoconstituents as Lead Compounds for Anti-dengue Drug Discovery -- 8 Anti-influenza Drug Discovery and Development: Targeting the Virus and its Host by all -- 9 Search, Identification and Design of Effective Antiviral Drugs against Pandemic Human Coronaviruses -- 10 Peptide Based Antiviral Drugs -- 11 Covalent Antiviral Agents -- 12 Safe-in-Man Broad Spectrum Antiviral Agents -- 13 Exploiting Ubiquitin ligases for Induced Target Degradation as an Antiviral Strategy. .
520 $a This book summarizes state-of-the-art antiviral drug design and discovery approaches starting from natural products to de novo design, and provides a timely update on recently approved antiviral drugs and compounds in advanced clinical development. Special attention is paid to viral infections with a high impact on the world population or highly relevant from the public health perspective (HIV, hepatitis C, influenza virus, etc.). In these chapters, limitations associated with adverse effects and emergence of drug resistance are discussed in detail. In addition to classical antiviral strategies, chapters will be dedicated to discuss the non-classical drug development strategies to block viral infection, for instance, allosteric inhibitors, covalent antiviral agents, or antiviral compounds targeting protein–protein interactions. Finally, current prospects for producing broad-spectrum antiviral inhibitors will be also addressed. The book is distinctive in providing the most recent update in the rapidly evolving field of antiviral therapeutics. Authoritative reviews are written by international scientists well known for their contributions in their topics of research, which makes this book suitable for researchers not only within the antiviral research community but also attractive to a broad audience in the drug discovery field. This book covers molecular structures and biochemical mechanisms mediating the antiviral effects, while discussing various ligand design strategies, which include traditional medicinal chemistry, computational chemistry, and chemical biology approaches. The book provides a comprehensive review of antiviral drug discovery and development approaches, particularly focusing on current innovations and future trends.
650 0 $a Pharmacology. $3 583819
650 0 $a Pharmacy. $3 582411
650 0 $a Biotechnology. $3 554955
650 1 4 $a Pharmacology/Toxicology. $3 593882
700 1 $a Liu, Xinyong. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1349739
700 1 $a Zhan, Peng. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1349740
700 1 $a Menéndez-Arias, Luis. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1349741
700 1 $a Poongavanam, Vasanthanathan. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1349742
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789811602665
776 0 8 $i Printed edition: $z 9789811602689
776 0 8 $i Printed edition: $z 9789811602696
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-981-16-0267-2
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)